Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …

BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea …

Objective: Chemotherapy‐induced nausea and vomiting (CINV) is a significant problem for
cancer patients. Aprepitant, a novel NK‐1 receptor antagonist, is approved for use with 5 …

Goals of work Certain patient and treatment characteristics are predictive of chemotherapy-
induced nausea and vomiting (CINV). Objectives of this analysis were:(1) confirm the …

Background: Nausea and vomiting is one of the most feared side effects of chemotherapy;
however, in the past 20 years, a better understanding of the pathophysiology of …

Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …

Purpose A number of studies have reported that aprepitant has been used to prevent
chemotherapy-induced nausea and vomiting. In this study, we aimed to analyze the efficacy …

In this work, data from two phase III studies were pooled to further evaluate the NK1
antagonist aprepitant for prevention of cisplatin induced nausea and vomiting. One …

Purpose Aprepitant was shown previously to be effective for prevention of chemotherapy-
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …

Aprepitant (Emend®) is the first commercially available drug from a new class of agents, the
neurokinin NK 1 receptor antagonists. Oral aprepitant, in combination with other agents, is …